ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1126

Safety Profile of SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Use in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Nawaz, Iqra, Stony Brook University, Stony Brook, New York, United States
  • Mallipattu, Sandeep K., Stony Brook University, Stony Brook, New York, United States
Background

The novel hypoglycemic agents SGLT2i and GLP-1RA have demonstrated combined reno and cardiovascular protective and mortality benefits. Multiple studies have extensively assessed the safety analyses and adverse events associated with these agents among patients with diabetes and cardiovascular disease. However, there is a paucity of data on the safety analyses of these agents among patients with chronic kidney disease.

Methods

TriNetX database was used to determine patients aged > 18 with CKD (eGFR 30-89) within the USA collaborative network from Jan 1st, 2015, to Dec 31st, 2023. The SGLT2i and GLP-1RA users and nonusers were propensity-scored matched on factors such as Diabetes, HTN, Heart failure, hyperlipidemia, obesity, use of Insulin, sulfonylureas, metformin, ACEi/ARBs, diuretics, and other hypoglycemic agents.

Results

Our results indicate that of 295,798 SGLT2i users and 9885755 non-users, 294567 patients were propensity-scored matched in both groups. The risk of UTI 3.7% (10062) in SGLT2i users, compared to 6.89% (17964) in non-users, genitourinary infections 1.8% (5284) vs. 2.7% (7803), Hypoglycemia 1.08% (3126) vs 1.5% (4358), bone fractures 0.23% (687) vs. 0.5% (1471), limb amputation 0.03% (104) vs 0.06% (192), ketoacidosis 0.14% (435) vs. 0.16 % (457), volume depletion 2.5% (7104) vs. 4% (11639). The risks of Vulvovaginitis are 0.007% (22) vs. 0.008% (23), vaginal candidiasis 3.6% (9978) vs. 3.8% (10837), Fournier gangrene 0.01% (40) vs. 0.019 % (56) were almost similar in both SGLT2I users and nonusers respectively. The results of adverse events comparison of GLP-1RA users with non users is shown in figure 1.

Conclusion

Overall, the results of our study demonstrate that the risks of adverse events in the SGLT2i and GLP-1RA users in patients with chronic kidney disease are relatively lower than in the nonuser groups.